Maternal care for anti-D [Rh] antibodies, third trimester (other fetus)
ICD-10 O36.0139 is a billable code used to indicate a diagnosis of maternal care for anti-d [rh] antibodies, third trimester (other fetus).
Maternal care for anti-D [Rh] antibodies during the third trimester is critical for managing potential fetal complications arising from Rh incompatibility. This condition occurs when an Rh-negative mother carries an Rh-positive fetus, leading to the production of anti-D antibodies that can cross the placenta and affect the fetus. In the third trimester, careful monitoring is essential as the risk of hemolytic disease of the newborn (HDN) increases. This can manifest as fetal growth restriction, fetal distress, or even fetal demise if not managed appropriately. Regular ultrasounds and Doppler studies are often employed to assess fetal well-being, monitor growth patterns, and evaluate blood flow in the umbilical artery. Maternal care may also include administering Rh immunoglobulin (RhoGAM) to prevent antibody formation in future pregnancies. The management of this condition requires a multidisciplinary approach, involving obstetricians, maternal-fetal medicine specialists, and pediatricians to ensure optimal outcomes for both mother and fetus.
Detailed records of maternal antibody testing, ultrasound findings, and management plans.
Management of a pregnant woman with known Rh incompatibility presenting for routine prenatal care.
Ensure accurate coding of fetal monitoring and any interventions performed.
Comprehensive documentation of high-risk assessments, including fetal echocardiograms and Doppler studies.
Consultation for a patient with rising anti-D antibody levels and evidence of fetal distress.
Focus on the implications of maternal health on fetal outcomes and the need for interdisciplinary communication.
Used for routine monitoring of fetal growth and well-being in patients with anti-D antibodies.
Document the indication for the ultrasound, findings, and any follow-up plans.
Ensure that the ultrasound is performed by a qualified technician and interpreted by a specialist.
Anti-D antibodies can lead to serious complications for the fetus, including hemolytic disease of the newborn. Monitoring and management are essential to prevent adverse outcomes.
